US2020317762A1PendingUtilityA1

COMPLEMENT FACTOR Bb ANTIBODIES

Assignee: ALLERGAN INCPriority: Feb 27, 2014Filed: Mar 27, 2020Published: Oct 8, 2020

Est. expiryFeb 27, 2034(~7.6 yrs left)· nominal 20-yr term from priority

Inventors:Yanbin Liang Chen Li Iris Lee Victor M. Guzman

C07K 16/18C07K 2317/24A61P 27/02A61K 2039/505C07K 2317/92A61K 45/06A61K 39/395

PatentIndex Score

Cited by

References

Claims

Abstract

The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.

Claims

exact text as granted — not AI-modified

We claim: 
     
         1 . A Factor Bb antibody, wherein the antibody binds to Factor Bb with greater affinity than to Factor B; and inhibits complement dependent hemolysis. 
     
     
         2 . The antibody of  claim 1 , that binds Factor Bb with a Kd of less than about 1 nM. 
     
     
         3 . The antibody of  claim 1 , wherein the antibody blocks formation of membrane attack complex (MAC) in a patient. 
     
     
         4 . The antibody of  claim 1  comprising a heavy chain and a light chain. 
     
     
         5 . The antibody of  claim 4 , wherein the light chain comprises an amino acid sequence at least 80% identical to a sequence selected from the group consisting of SEQ ID NO:8-11; and wherein the heavy chain comprises an amino acid sequence at least 80% identical to a sequence selected from the group consisting of SEQ ID NO:12-15. 
     
     
         6 . The antibody of  claim 4 , wherein the light chain comprises an amino acid sequence at least 80% identical to a sequence selected from the group consisting of SEQ ID NO:24-27; and wherein the heavy chain comprises an amino acid sequence at least 80% identical to a sequence selected from the group consisting of SEQ ID NO:28-31. 
     
     
         7 . The antibody of  claim 4 , wherein the antibody is an antibody comprising a heavy chain and a light chain variable domain selected from the heavy and light chain variable sequences: SEQ ID NO:8/SEQ ID NO:12; SEQ ID NO:8/SEQ ID NO:13; SEQ ID NO:8/SEQ ID NO:14; SEQ ID NO:8/SEQ ID NO:15; SEQ ID NO:9/SEQ ID NO:12; SEQ ID NO:9/SEQ ID NO:13; SEQ ID NO:9/SEQ ID NO:14; SEQ ID NO:9/SEQ ID NO:15; SEQ ID NO:10/SEQ ID NO:12; SEQ ID NO:10/SEQ ID NO:13; SEQ ID NO:10/SEQ ID NO:14; and SEQ ID NO:10/SEQ ID NO:15; SEQ ID NO:11/SEQ ID NO:12; SEQ ID NO:11/SEQ ID NO:13; SEQ ID NO:11/SEQ ID NO:14; and SEQ ID NO:11/SEQ ID NO:15. 
     
     
         8 . The antibody of  claim 4 , wherein the antibody is an antibody comprising a heavy chain and a light chain variable domain selected from the light and heavy chain variable domain amino acid sequences: SEQ ID NO:24/SEQ ID NO:28; SEQ ID NO:24/SEQ ID NO:29; SEQ ID NO:24/SEQ ID NO:30; SEQ ID NO:24/SEQ ID NO:31; SEQ ID NO:25/SEQ ID NO:28; SEQ ID NO:25/SEQ ID NO:29; SEQ ID NO:25/SEQ ID NO:30; SEQ ID NO:25/SEQ ID NO:31; SEQ ID NO:26/SEQ ID NO:28; SEQ ID NO:26/SEQ ID NO:29; SEQ ID NO:26/SEQ ID NO:30; and SEQ ID NO:26/SEQ ID NO:31; SEQ ID NO:27/SEQ ID NO:28; SEQ ID NO:27/SEQ ID NO:29; SEQ ID NO:27/SEQ ID NO:30; and SEQ ID NO:27/SEQ ID NO:31. 
     
     
         9 . The antibody of  claim 4 , wherein antibody comprises a light chain variable domain amino acid sequence of SEQ ID NO:11 and a heavy chain variable domain amino acid sequence of SEQ ID NO:15. 
     
     
         10 . The antibody of  claim 1 , wherein said antibody is a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof. 
     
     
         11 . The antibody of  claim 10 , wherein said antibody fragment is a Fab fragment, a Fab′ fragment, a F(ab′) 2  fragment, a Fv fragment, a diabody, or a single chain antibody molecule. 
     
     
         12 . The antibody of  claim 10 , wherein said antibody is of the IgG1-, IgG2- IgG3- or IgG4-type. 
     
     
         13 . The antibody of  claim 1 , wherein said antibody is coupled to a labeling group. 
     
     
         14 . A process for preparing an isolated antibody of  claim 1 , comprising preparing said antibody from a host cell that secretes said antibody. 
     
     
         15 . A nucleic acid molecule encoding an isolated antibody of  claim 1 . 
     
     
         16 . A pharmaceutical composition comprising the antibody of  claim 1  and pharmaceutically acceptable carrier. 
     
     
         17 . The pharmaceutical composition of  claim 16 , further comprising an additional active agent. 
     
     
         18 . A method for treating or preventing a condition in a patient in need of treatment or prevention comprising administering to said patient an effective amount of the antibody of  claim 1 ; and thereby treating or preventing the condition. 
     
     
         19 . The method of  claim 18 , wherein the condition is an ocular disease. 
     
     
         20 . The method of  claim 19 , wherein the condition is age-related macular degeneration (AMD).

Join the waitlist — get patent alerts

Track US2020317762A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.